DPS References






Myeloid Novel Digital Pathology Tools for Exploring Role of Myeloid Cells in Modulating Next Generation Immunotherapies   AACR 2023
MSI High Tumor DNA damage response assessment after WRN inhibition in MSI high tumors: mIF assays validation for preclinical and clinical evaluation   NIBR ONC Retreat
DLBCL Tissue-based Biomarker Analysis of DLBCL using Multiplex Immunofluorescence AQUA (auotmated quantitative analysis) algorithms   AACR
Melanoma Tumor-infiltrating B cells play a role in determining clinical outcome after BRAF and MEK inhibition Clinical Cancer Research  
solid tumor Exploring the interplay between TAM, PD-L1 and immunosuppressive molecules by a novel multiplex immunofluorescence assay in cancer immunotherapy trials   AACR
RCC Clinical features and multiplatform molecular analysis assist in understanding patient response to anti-PD-1/PD-L1 in renal cell carcinoma Cancers  
Solid tumor Novel Approach for Profiling Immune-Tumor Cell Interactions and Mutations in the Same Tumor Section by Multiplex Immunohistochemistry and NGS in Immuno-Oncology Trials   SITC
Solid tumor Pathologists Enhance Interpretation of Automated Multiplex Immunohistochemistry Assays in Cancer Immunotherapy Trials   SITC
Breast MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC JCI Insight  
GBM Predictive Evaluation of Quantitative Spatial Profiling of the Tumor Microenvironment by Multiplex Immunofluorescence in Recurrent Glioblastoma Treated with PD-1 Inhibitors   ASCO
Solid tumor Immunophenotyping Tumors by Novel Multiplex Immunofluorescence and AQUA (Automated Quantitative Analyses) Algorithms to Guide Development of Immunotherapies   AACR
Solid Tumor Immuno-Oncology Biomarkers Identified by Novel Digital Pathology Approaches   MarketsandMarkets Biomarker and Companion Diagnostics
Breast The immune landscape of residual triple-negative breast cancers after neoadjuvant chemotherapy.    SABCS
SCLC Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.  Journal of Thoracic Oncology ASCO
Breast MEK activation modulates immunosuppressive MDSC and metabolic programs in TNBC   AACR
Breast Molecular characterization of residual triple-negative breast cancers after neoadjuvant chemotherapy identifies immune composition and features associated with clinical outcome   AACR
DLBCL PD-1/PD-L1 expression and interaction in the microenvironment of DLBCL by Quantitative Immunofluorescent Analysis.  Modern Pathology ASCO
Solid Tumors Tumor-specific major histocompatibility complex class II (MHC-II) expression drives a unique pattern of adaptive resistance to immunotherapy through MHC-II receptor engagement. Journal of Clinical Investigations  ASCO
Melanoma Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma  Clinical Cancer Research ASCO
Melanoma Characterization of the tumor immune microenvironment following ipilimumab and IFNα2b neoadjuvant therapy in melanoma   SITC
SCCHN IDO/HLA-DR expression and tumor mutational burden are complementary predictive biomarkers of anti-PD-1 immunotherapy in squamous cell carcinoma of head and neck   SITC
Melanoma & NSCLC Development of clinical-grade multiplex F-IHC assays to quantify spatial distribution of PD-L1.    NIBR Onc Retreat
Multi Multiplex FIHC and AQUA Analysis for I-O Clinical Trials: Challenges & Successes   NHS
NSCLC Tumor PD-L1 heterogeneity in non-small cell lung cancer: Does biopsy size and volume matter?   ASCO
NSCLC PD-1/PD-L1 Interaction and CD25/FOXP3+ T cells Predict Survival Benefit from Adjuvant Chemotherapy in Early Stage Non–Small-Cell Lung Cancer (ES-NSCLC)   ASCO
DLBCL Biomarker analysis of tisagenlecleucel pre-infusion biopsies of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)    EHA
SCLC Clinical Outcomes and Differential Tumor Immune Infiltrate and PD-1/PD-L1 Expression in Tumors from Patients with Small Cell Lung Cancer and Paraneoplastic Syndromes    AACR
Melanoma, Lung Novel Multiplexed Digital Pathology Algorithms Identify Superior Predictors of anti-PD-1 Response: A Real World Study    Tri-Con
Breast MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through receptor checkpoint engagement.   ASCO-SITC
Breast Breast tumor-specific MHC-II expression drives a unique pattern of adaptive resistance to antitumor immunity through MHC-II receptor checkpoint engagement.   SABCS
DLBCL Clinical significance of PD-1 and PD-L1 expression and ongoing interaction in the tumor microenvironment in diffuse large B cell lymphoma (DLBCL) treated with R-CHOP   ASH
NSCLC Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy in Early Stage Non–Small-Cell Lung Cancer    IASLC
Melanoma Chronic Granulomatous Dermatitis Induced by Talimogene Laherparepvec Therapy of Melanoma Metastases Journal of Cutaneous Pathology ASCO
Solid Immuno-Oncology biomarker assessment by novel digital imaging algorithms based on AQUA Technology   NSH
Breast Multiplexed ion-beam imaging (MIBI) analysis for quantitation of protein expression on cancer tissue sections Laboratory Investigation  
Melanoma Unique biomarker signatures identified by novel quantitative immunohistochemistry algorithms predict outcomes to PD-1 blockers in metastatic melanoma patients   Immuno-Oncology Summit
Melanoma Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec. JAAD Case Reports ASCO
Melanoma Quantitative spatial profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 predicts improved outcomes to anti-PD-1 in metastatic melanoma   ASCO
Testicular Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling. OncoImmunology ASCO
Renal  Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic Renal Medullary Carcinoma Journal for Immunotherapy of Cancer ASCO
Melanoma Novel quantitative multiplexed PD-1/PD-L1 immunohistochemistry test provides superior prediction of treatment response in melanoma patients   AACR
Solid Tumor Novel automated quantitative analysis (AQUA) algorithms for reproducible assessment of PD1-PD-L1 interaction and immune cell subsets by multiplex fluorescence immunohistochemistry in cancer immunotherapy trials.    Tri-Con
ALL Quantitative multiplexed immunohistochemistry assays for exploring CAR modified T cells and checkpoint inhibitors in lymphoma trials   ASH
CRC Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins. Oncotarget ASCO
Breast In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients. PLoS One ASCO
Breast Development of a binary diagnostic immunofluorescence assay by AQUA® technology for accurate detection of HER-2 levels in breast cancer specimens.    AACR
Breast Evaluation of HER2 RNA and Protein Levels in a Large Cohort of Breast Cancer Specimens to Support Development of a Diagnostic Immunofluorescence Assay Quantified by AQUA® Technology.    AACR
Breast Development of a clinical targeted next generation sequencing test for challenging formalin-fixed paraffin-embedded (FFPE) cancer samples   AACR
Breast Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method PLoS One ASCO